Definitive Contract HHSN261201600050C
Award Date
9/19/16
Potential Completion Date
6/18/17
Potential Value
$300K
Federal Agency
National Cancer Institute
Awardee
Ultivue Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02138, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
<p>The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute awarded a Firm Fixed Price purchase order contract to Ultivue Inc., a for-profit organization, for the provision of Biological Kits. The contract, which does not have a set-aside designation, is valued at $24,940.00 and has a completion date of June 1, 2024. The place of performance is Cambridge, MA 02138, USA.</p>
<p>The National Cancer Institute, a civilian federal agency, awarded a firm-fixed-price purchase order contract worth $14,000.00 to Ultivue Inc. for software. The contract has a period of performance that extends through September 14, 2025. This contract award is not associated with a set-aside program.</p>
<p>This is a firm fixed-price purchase order contract awarded to Ultivue Inc. by the National Cancer Institute, a civilian federal agency, for software. The contract has a ceiling value of $15,000.00 and an ultimate completion date of September 14, 2025. The contract was awarded on September 15, 2024 and does not have a set-aside designation. No further details about the software requirements or a larger contracting vehicle are provided.</p>
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, has awarded a firm fixed-price purchase order valued at $24,940 to Global Life Sciences Solutions USA LLC. The contract calls for the delivery of an imaging system and associated easy-to-use software for band analysis and quantification of protein and DNA gels. The products and services will support research activities across the Laboratory of Biochemistry and...
<p>This is a $994,198.78 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Precision For Medicine (TX), Inc. on September 20, 2013. The contract is for research and development in biomedical (basic research) and has a period of performance through September 19, 2015. The contract is designated as a total small business set-aside.</p>
This federal contract award is for the delivery of biological kits to the National Cancer Institute, which is part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The prime contractor is Illumina, Inc., a manufacturer and provider of sequencing and analytical solutions for life science research, applied markets, and molecular diagnostics. The $140,301.60 firm fixed price contract has a completion date of July 25, 2019. No set-aside designation...
This is a $399,062 firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI) to Avoneaux Medical Institute, LLC for the development of spatial micro-purification technology. The contract was set aside for small businesses and is part of the NCI's broader SBIR program, which funds research and development in support of the NIH and CDC's mission needs. The original solicitation sought proposals on a range of cancer-related topics, including alternatives to cell...
The Department of Health and Human Services National Institutes of Health National Cancer Institute (HHS-NIH-NCI) awarded a $93,969.03 firm fixed price delivery order contract to Illumina, Inc. for reagents and consumables. The place of performance will be Illumina's facilities located in San Diego, California. The period of performance is from December 20, 2023 through January 19, 2024. This delivery order was awarded under an existing government-wide acquisition contract vehicle or blanket...
This is a $199,892.00 federal contract awarded by the National Cancer Institute, a civilian agency, to Eutropics Pharmaceuticals, a for-profit small business. The contract is for basic research and development in the "OTHER FUNCTIONS R & D- BIOMEDICAL (BASIC RESEARCH)" domain as part of the SBIR Program Phase I. The contract is a definitive, firm fixed-price agreement with a completion date of June 21, 2013. This contract award has a total small business set-aside designation.